Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Nkarta Inc(NKTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for NKTX
09/25/2026: NKTX (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Nkarta Inc is a clinical-stage biotechnology company focused on developing off-the-shelf natural killer cell therapies for cancer. Its primary strengths lie in a specialized engineering platform and in-house manufacturing capabilities that aim to create scalable, lower-toxicity treatments. The investment story centers on the potential for its clinical-stage assets, NKX101 and NKX019, to establish a foothold in the competitive oncology landscape. Key risks include the binary nature of clinical trials, substantial cash burn, and intense competition from established CAR-T providers. This stock is best suited for risk-tolerant growth investors who should monitor upcoming clinical readouts and liquidity levels closely.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Nkarta offers high-risk, high-reward exposure to biotechnology innovation. |
| Momentum investor | Mixed fit | Momentum is conditional on positive clinical data readouts and sector-wide sentiment. |
| Value investor | Weak fit | The company currently lacks earnings and revenue, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and reinvests all capital. |
| Low-risk investor | Weak fit | Clinical-stage biotech involves significant volatility and binary trial outcomes. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often experience rapid fluctuations based on news cycles. |
| Valuation risk | High | Valuations are driven by speculative future potential rather than current fundamentals. |
| Competition risk (oncology therapeutics) | High | Established players have massive R&D budgets and existing infrastructure. |
| Business quality | Medium | The company possesses specialized science but remains at the mercy of R&D success. |
| Dividend income | Low / none | There is no income generation for investors. |
| Execution risk | High | Success depends on complex clinical trial completion and regulatory approval. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 35.61% | Avg. Invested days 24 | Today’s Advisory WEAK BUY |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 196.97M USD | Price to earnings Ratio - | 1Y Target Price 10.83 |
Price to earnings Ratio - | 1Y Target Price 10.83 | ||
Volume (30-day avg) 586.0K shares | Beta 0.97 | 52 Weeks Range 1.70 - 3.72 | Updated Date 09/26/2026 |
52 Weeks Range 1.70 - 3.72 | Updated Date 09/26/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.58 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Cell Therapy R&D | Clinical trial development for NKX101 and NKX019. | The company is currently spending money to research treatments, not generating product revenue. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 87.74M | Price to Sales(TTM) 1000000 |
Enterprise Value 87.74M | Price to Sales(TTM) 1000000 | ||
Enterprise Value to Revenue 1000000 | Enterprise Value to EBITDA 0.95 | Shares Outstanding 71.62M | Shares Floating 60.52M |
Shares Outstanding 71.62M | Shares Floating 60.52M | ||
Percent Insiders 4.88 | Percent Institutions 82.8 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Nkarta Inc
Exchange NASDAQ | Headquarters South San Francisco, CA, United States | ||
IPO Launch date 2020-07-10 | CEO & Director Mr. Paul J. Hastings | ||
Sector Healthcare | Industry Biotechnology | Full time employees 106 | Website https://www.nkartatx.com |
Full time employees 106 | Website https://www.nkartatx.com | ||
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.